Anti-PPAR gamma antibody (Biotin) (ab48373)
- Storage instructionsStore at +4°C short term (1-2 weeks). Store at -20°C or -80°C. Avoid freeze / thaw cycle.
- Storage bufferPreservative: 0.01% Thimerosal (merthiolate)
Constituents: 50% Glycerol, PBS, pH 7.5
- Concentration information loading...
- PurityProtein G purified
- Clonality Polyclonal
- Pathways and Processes
- Metabolic signaling pathways
- Lipid and lipoprotein metabolism
- Fatty acids
Our Abpromise guarantee covers the use of ab48373 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|RIA||RIA: Use at an assay dependent dilution.|
|WB||WB: Use at an assay dependent dilution. Predicted molecular weight: 58 kDa.|
- FunctionReceptor that binds peroxisome proliferators such as hypolipidemic drugs and fatty acids. Once activated by a ligand, the receptor binds to a promoter element in the gene for acyl-CoA oxidase and activates its transcription. It therefore controls the peroxisomal beta-oxidation pathway of fatty acids. Key regulator of adipocyte differentiation and glucose homeostasis.
- Tissue specificityHighest expression in adipose tissue. Lower in skeletal muscle, spleen, heart and liver. Also detectable in placenta, lung and ovary.
- Involvement in diseaseNote=Defects in PPARG can lead to type 2 insulin-resistant diabetes and hyptertension. PPARG mutations may be associated with colon cancer.
Defects in PPARG may be associated with susceptibility to obesity (OBESITY) [MIM:601665]. It is a condition characterized by an increase of body weight beyond the limitation of skeletal and physical requirements, as the result of excessive accumulation of body fat.
Defects in PPARG are the cause of familial partial lipodystrophy type 3 (FPLD3) [MIM:604367]. Familial partial lipodystrophies (FPLD) are a heterogeneous group of genetic disorders characterized by marked loss of subcutaneous (sc) fat from the extremities. Affected individuals show an increased preponderance of insulin resistance, diabetes mellitus and dyslipidemia.
Genetic variations in PPARG can be associated with susceptibility to glioma type 1 (GLM1) [MIM:137800]. Gliomas are central nervous system neoplasms derived from glial cells and comprise astrocytomas, glioblastoma multiforme, oligodendrogliomas, and ependymomas. Note=Polymorphic PPARG alleles have been found to be significantly over-represented among a cohort of American patients with sporadic glioblastoma multiforme suggesting a possible contribution to disease susceptibility.
- Sequence similaritiesBelongs to the nuclear hormone receptor family. NR1 subfamily.
Contains 1 nuclear receptor DNA-binding domain.
- Cellular localizationNucleus.
- CIMT1 antibody
- GLM1 antibody
- HUMPPARG antibody
- NR1C3 antibody
- Nuclear receptor subfamily 1 group C member 3 antibody
- OTTHUMP00000185032 antibody
- OTTHUMP00000185036 antibody
- Peroxisome proliferator activated nuclear receptor gamma variant 1 antibody
- Peroxisome proliferator activated receptor gamma 1 antibody
- Peroxisome Proliferator Activated Receptor gamma antibody
- Peroxisome proliferator-activated receptor gamma antibody
- PPAR gamma antibody
- PPAR-gamma antibody
- PPARG antibody
- PPARG_HUMAN antibody
- PPARG1 antibody
- PPARG2 antibody
- PPARG3 antibody
References for Anti-PPAR gamma antibody (Biotin) (ab48373)
ab48373 has not yet been referenced specifically in any publications.